Colorectal cancer is the third most common cancer in. rezime ... Multimodal Treatment of Metastatic Colorectal Cancer
|
|
- Erick Wade
- 5 years ago
- Views:
Transcription
1 /STRU^NI RAD / : Multimodal Treatment of Metastatic Colorectal Cancer... Irene Kuehrer University Clinic of Surgery, General Hospital of Vienna Background: Metastases to the liver is the leading cause of death in patients with colorectal cancer. Methods: The authors review the data on diagnosis and management of this clinical problem, and they discuss management options that can be considered. Results: Complete surgical resection of metastases from colorectal cancer that are localized to the liver results in 5-year survival rates ranging from 26% to 40%. Conclusions: By adding modalities such as targeted systemic therapy and other "local" treatments for liver metastases, further gains in survival are anticipated Key words: liver metasases, surgical resection, neoadjuvant chemotherapy, extrahepatic disease, survival benefit rezime INTRODUCTION Colorectal cancer is the third most common cancer in both men and women. About 50% of patients diagnosed with CRC will die from their disease, accounting for about 10% of all cancer deaths. Tremendous strides are made regularly in the prevention, diagnosis, and treatment of colorectal cancer, posing a challenge to the clinician who must stay abreast of the most recent advances. In the 1970s, treatment options for patients with advanced colorectal cancer were limited to the fluoropyrimidine 5-fluorouracil (5-FU). Since that time, newer cytotoxic agents, such as capecitabine, irinotecan, and oxaliplatin, have been introduced, extending survival, facilitating administration, and permitting better tailoring of treatment regimens to individual patients. The last 3 years have seen yet further advances with the approval of biologic agents such as bevacizumab in front-line therapy and cetuximab in second- and third-line therapy. The more aggressive chemotherapy regimens can not only control the disease, but also render some advanced metastatic disease into a resectable stage. BACKGROUND: The natural history of colorectal cancer metastasis in the majority of patients is dismal. Historically, the median survival is 6 to 12 months if untreated. Even with newer therapeutics such as irinotecan or oxaliplatin, the 5-year survival rate with nonsurgically treated hepatic metastases is low. In contrast, those who undergo a complete resection have 5-year survival rates of 25% to 40%. It can be argued that the patients who undergo resection are selected and may have better outcomes because they have less virulent disease. A trial designed to compare resection vs systemic therapy is unlikely until more efficacious systemic therapy regimens are discovered. Currently, the survival rates reported after curative hepatic resections are 25% to 39% for 5 years and 22% to 23% for 10 years. RESECTION OF EXTRAHEPATIC COLORECTAL ME- TASTASES Once suspected, colorectal liver metastases are staged by spiral CT, CT portography and MRI, which have similar overall accuracies. Mortality following liver resection is less than 5% in major centres, with a morbidity rate of 20% to 50%. Prognostic scoring systems can be used to predict the likely cure rate with resection. Pulmonary metastases occur in 10-25% of patients with resected colorectal cancer, but are limited to the lung in only 2% of cases. In these selected cases surgery provides long-term survival in 20-40%, and repeat lung resection has shown similar rates. The presence of thoracic lymph node involvement and elevated carcinoembryonic antigen level before pulmonary resection are associated with reduced survival. For patients with unresectable disease, chemotherapy and ablation techniques have been demonstrated to prolong survival, although chemotherapy alone has been shown to improve quality of life.
2 52 I. Kuehrer ACI Vol. LIII LIVER RESECTION FOR COLORECTAL METASTASES Surgical resection is associated with the best chance for cure of colorectal cancer when complete resection of the tumor-bearing liver can be accomplished. However, historically, only 10% to 20% of patients with colorectal liver metastases have been eligible for resection with radical intent. Recent improvements in preoperative imaging techniques, patient selection, and surgical techniques, as well as the introduction of new cytotoxic and biologic agents for preoperative and postoperative chemotherapy have improved the resectability rate and almost doubled the 5-year survival rate for patients with colorectal liver metastases, from about 30% two decades ago to nearly 60%.Moreover, in patients with nonresectable metastases, modern chemotherapy alone extends median survival to 2 years or more, and 20% of patients with nonresectable metastases are still alive 4 years after detection of nonoperable liver disease. In summary, the care of patients with hepatic colorectal metastases has rapidly changed. Novel chemotherapeutic regimens combining 5-FU, folinic acid, and oxaliplatin and/or irinotecan have been associated with improved response rates (approximately 50%), allowing 10% to 30% of the patients with initially unresectable disease to be successfully treated with liver surgery. In addition, early results from trials evaluating novel biologic agents that target angiogenesis and the epidermal growth factor receptor, bevacizumab and cetuximab, suggest that even more patients with initially unresectable disease may respond to primary treatment with combinations of systemic therapies (response rates up to 70%). NEOADJUVANT THERAPY Most patients with colorectal liver metastases will present with unresectable disease. Beginning in the 1990s, Bismuth et al reported on a small percentage of patients who had a significant downsizing of their hepatic lesion with neoadjuvant chemotherapy. These patients were then brought to surgery for an attempted R0 resection. The 5- year survival rate was 40%, similar to those resected de novo. These results have been reproduced multiple times. Therefore, those patients initially determined to be unresectable should be reevaluated for resectability after neoadjuvant therapy for resectability. More recently, newer effective chemotherapeutic combinations, including FOL- FOX or FOLFIRI with bevacizumab, have had more consistent results in downsizing liver metastases from colorectal adenocarcinoma. There is no evidence to support pretreatment with neoadjuvant chemotherapy in patients with respectable disease also response might be a surrogate maker for curative resection and studies will shoe the impact of adjuvant therapy after liver resection. 20% will progress while on chemotherapy and will have no benefit from subsequent liver resection. RECURRENCE FOLLOWING LIVER RESECTION Approximately 60% to 70% of patients treated with resection will recur. Of those who recur, 30% of recurrences will be isolated to the liver. The liver parenchyma will regenerate or hypertrophy to presurgical size in 3 to 6 months, and significant resection can be performed a second time if the patient s physical status will allow repeat procedures. Several studies have demonstrated similar morbidity and mortality compared to primary resection. The overall 5-year survival is similar to that of the initial resections and the timetable is reset from the time of the second resection. A recent retrospective study by Petrowsky et al demonstrated similar morbidity and mortality rates compared to primary resection, with a 34% actuarial 5-year survival rate and 15% actual 5-year survivors at the time of follow-up. These results are similar to those published for primary resections and suggest that reintervention is of benefit.the recent emergence of molecularly targeted monoclonal antibody therapiewith proven efficacy in metastatic colorectal cancer, provides a significant improvement in the outcomes for patients, but also presenting challenges for clinicians in selecting the most appropriate combination of therapy for their patients after liver resection. FOLLOW-UP AFTER RESECTION: Postoperative surveillance evaluates the efficacy of treatment as well as screening for recurrence. According to the 2006 National Comprehensive Cancer Network guidelines, follow-up includes a physical examination, a CEA measurement, and a CT scan of the chest and abdomen every 3 months for 2 to 3 years, then every 6 months for 5 years. Some clinicians limit the use of CT scan until a measurable CEA level is noted. Most recurrences are identified within the first 2 years of operation. The surveillance begins again if a patient has had a re-resection of a liver lesion. A recurrence beyond 5 years of intervention is rare; therefore, routine imaging and laboratory followup other than screening colonoscopy are unnecessary CONCLUSIONS With the addition of newer chemotherapeutics, survival has improved in patients treated both medically and surgically for metastatic colorectal cancer. The role of neoadjuvant chemotherapy is being clarified. The current approach is upfront surgery unless a lesion is considered unresectable. Neoadjuvant therapy may soon be recommended more frequently, however, as more predictable responses from the intervention occur. During the preoperative evaluation, attention needs to be focused on considering sufficient liver parenchyma and assessment for extrahepatic disease. Survival benefits in patients undergoing a second liver resection have similar outcomes as those undergoing a primary resection. Regardless of the surgical resection, patients benefit most when tumor-free margins greater than 1 cm are achieved. If the margins are close, RFA or cryotherapy can be added to ensure an adequate depth. SUMMARY Hepatic metastases occur in 60% of patients following resection for colorectal cancer. Liver resection is the only curative option, with one third of resected patients alive at five years. In those developing recurrence in the liver fol-
3 Br. 2 Multimodal treatment of metastatic colorectal cancer 53 lowing resection, further liver surgery may be curative, with similar 5 years survival rates of about 30%. Until recently surgery was feasible in only 15-25% of patients with colorectal liver metastases. New strategies, such as downstaging chemotherapy, portal vein embolization and two-stage hepatectomy, may increase the resectability rate by 15%. Earlier detection of liver metastases would increase resectability, although good follow-up trials are lacking. SUMMARY MULTIMODALNO LE^ENJE METASTATSKOG KOLOREKTALNOG KARCINOMA Uvod: Metastatska bolest jetre je vode}i uzrok smrti bolesnika sa kolorektalnim karcinomom. Materijal i metode: Autori analiziraju podatke iz literature u vezi sa dijagnozom i le~enjem metastatske bolesti jetre i diskutuju o mogu}im na~inima le~enja. Rezultati: Radikalna hirur{ka resekcija metastaza u jetri poreklom od kolorektalnog karcinoma omogu}ava petogodi{nje pre ivljavanje u 26 do 40% bolesnika. Zaklju~ak: Dodavanjem drugih modaliteta le~enja kao {to su ciljana sistemska hemioterapija i drugi vidovi lokalne terapije metastaza, mogu se posti}i bolji rezultati u le~enju metastatske bolesti jetre. Klju~ne re~i: metastaze u jetri, hirur{ka resekcija, neoadjuvantna hemoterapija, ekstrahepati~na bolest, pre ivljavanje REFERENCES 1. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240: Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350: Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56: Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224: ; discussion Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg. 2000;231: Bozzetti F, Bignami P, Montalto F, et al. Repeated hepatic resection for recurrent metastases from colorectal cancer. Br J Surg. 1992;79: Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235: Cunningham D, Humblett Y, Siena S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol. 2003;22:252. Abstract Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16: Epub 2005 Jan DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4: Desch CE. Post-treatment surveillance for colorectal cancer. American Society of Clinical Oncology Educational Book; 2006: Fernandez-Trigo V, Shamsa F, Sugarbaker PH. Repeat liver resections from colorectal metastasis. Repeat Hepatic Metastases Registry. Surgery. 1995;117: Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15: Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230: Fuchs C, Marshall J, Mitchell E, et al. A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Proc Am Soc Clin Oncol. 2006;24:147s. Abstract Fujita S, Akasu T, Moriya Y. Resection of synchronous liver metastases from colorectal cancer. Jpn J Clin Oncol. 2000;30: Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol. 1999;10: Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22: Epub 2003 Dec Heslin MJ, Medina-Franco H, Parker M, et al. Colorectal hepatic metastases: resection, local ablation, and hepatic artery infusion pump are associated with prolonged survival. Arch Surg. 2001;136: Erratum in: Arch Surg. 2001;136: Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mcrc): final analysis of the TREE-Study. Proc Am Soc Clin Oncol. 2006;24:148s. Abstract Hohenberger P, Schlag P, Schwarz V, et al. Tumor recurrence and options for further treatment after resection of liver metastases in patients with colorectal cancer. J Surg Oncol. 1990;44: Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil,
4 54 I. Kuehrer ACI Vol. LIII 23. Jaffe BM, Donegan WL, Watson F, et al. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet. 1968; 127: Jenkins LT, Millikan KW, Bines SD, et al. Hepatic resection for metastatic colorectal cancer. Am Surg. 1997;63: Kamel IR, Bluemke DA. MR imaging of liver tumors. Radiol Clin North Am. 2003;41: Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46:S22-S Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol. 2003;21: Lahr CJ, Soong SJ, Cloud G, et al. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol. 1983;1: Leonard GD, Brenner B, Kemeny NE, et al. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2005;23: Lorenz M, Staib-Sebler E, Hochmuth K, et al. Surgical resection of liver metastases of colorectal carcinoma: short and long-term results. Semin Oncol. 2000;27(5 Suppl 10): Lyass S, Zamir G, Matot I, et al. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol. 2001;78: Martin R, Paty P, Fong Y, et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003;197: Metcalfe M, Mann C, Mullin E, et al. Detecting curable disease following hepatectomy for colorectal metastases. ANZ J Surg. 2005;75: Moertel CG, Gunderson LL, Mailliard JA, et al. Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol. 1994;12: Morris DL. Surgery for liver metastases: how many? ANZ J Surg. 2002;72: Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77: Nordlinger B, Peschaud F, Malafosse R. Resection of liver metastases from colorectal cancer: how can we improve results? Colorectal Dis. 2003;5: Okano K, Yamamoto J, Okabayashi T, et al. CT imaging of intrabiliary growth of colorectal liver metastases: a comparison of pathological findings of resected specimens. Br J Radiol. 2002;75: Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, CA Cancer J Clin. 2005;55: Petrowsky H, Gonen M, Jarnagin W, et al. Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg. 2002;235: Pfister DG, Benson AB 3rd, Somerfield MR. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med. 2004;350: Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol. 2005;23: Poston GJ. Surgical strategies for colorectal liver metastases. Surg Oncol. 2004;13: Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15: Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15: Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992;216: Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer. 2002;38: Sahani DV, Kalva SP. Imaging the liver. Oncologist. 2004;9: Saini S. Imaging of the hepatobiliary tract. N Engl J Med. 1997;336: Scheele J, Altendorf-Hofmann A, Grube T, et al. Resection of colorectal liver metastases: what prognostic factors determine patient selection? [in German] Chirurg. 2001;72: Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg. 1995;19: Stangl R, Altendorf-Hofmann A, Charnley RM, et al. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343: Tournigand C, Andre T, Achille E, et al. FOLFIRI follo wed by FOL-FOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22: Epub 2003 Dec Valls C, Andia E, Sanchez A, et al. Hepatic metastases from colorectal cancer: preoperative detection and assessment of resectability with helical CT. Radiology Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Ann Surg. 1984;199: Wein A, Riedel C, Kockerling F, et al. Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-
5 Br. 2 Multimodal treatment of metastatic colorectal cancer 55 hour infusion of high-dose 5-fluorouracil and folinic acid. Ann Oncol. 2001;12: Wong SL, Edwards MJ, Chao C, et al. Radiofrequency ablation for unresectable hepatic tumors. Am J Surg. 2001;182: Wray CJ, Lowy AM, Mathews JB, et al. The significance and clinical factors associated with a subcentimeter resection of colorectal liver metastases. Ann Surg Oncol. 2005;12: Epub 2005 Mar Yamaguchi J, Yamamoto M, Komuta K, et al. Hepatic resections for bilobar liver metastases from colorectal cancer. J Hepatobiliary Pancreat Surg. 2000;7:
Treatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationRisk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis
ORIGINAL ARTICLE pissn 2288-6575 eissn 2288-6796 http://dx.doi.org/10.4174/astr.2016.90.5.257 Annals of Surgical Treatment and Research Risk factors for cancer recurrence or death within 6 months after
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric,
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationState of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationCorrespondence should be addressed to Roland Andersson,
Gastroenterology Research and Practice Volume 2012, Article ID 568214, 4 pages doi:10.1155/2012/568214 Research Article Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary
More informationPredictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy
Original Article Predictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy Rebecca C. Auer, MD 1 ; Rebekah R. White, MD 2 ; Nancy E. Kemeny, MD
More informationAggressive surgery in the multimodality treatment of liver metastases from colorectal cancer
Journal of BUON 12: 209-213, 2007 2007 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Aggressive surgery in the multimodality treatment of liver metastases from colorectal cancer N.
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationSurvival Outcomes of Liver Metastasectomy in Colorectal Cancer Cases: A Single-Center Analysis in Turkey
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.13.5195 Survival after Liver Metastasectomy in Colorectal Cancer Cases in Turkey RESEARCH ARTICLE Survival Outcomes of Liver Metastasectomy in Colorectal Cancer
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationRepeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.
Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome. Jönsson, Kristoffer; Gröndahl, Gerd; Salö, Martin; Tingstedt,
More informationHepatic resection for colorectal liver metastases: prospective study
Key words: Colorectal neoplasms; Hepatectomy; Survival analysis CL Liu ST Fan CM Lo WL Law IOL Ng J Wong Hong Kong Med J 2002;8:329-33 The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road,
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationQuality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma
1389 Quality of Survival Reporting in Chemotherapy and Surgery Trials in Patients with Metastatic Colorectal Carcinoma Robert C. G. Martin, M.D. 1,2 Vedra A. Augenstein, M.D. 1,2 Charles R. Scoggins, M.D.
More informationTumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in Patients with Colorectal Liver Metastases
Ann Surg Oncol DOI 1.1245/s1434-9-887-5 ORIGINAL ARTICLE HEPATOBILIARY TUMORS Tumor Marker Evolution: Comparison with Imaging for Assessment of Response to Chemotherapy in with Colorectal Liver Metastases
More informationNew Options in Metastatic Colorectal Cancer. Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka
New Options in Metastatic Colorectal Cancer Jeffrey A. Bubis, DO, FACOI, FACP Fleming Island Baptist South Palatka 4 th most frequently diagnosed CA in the US 2 nd leading cause of CA death in the US Incidence
More informationSimultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis
Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastasis Robert Martin, MD, Philip Paty, MD, Yuman Fong, MD, FACS, Andrew Grace, MD, Alfred Cohen, MD, FACS, Ronald
More informationMetastatic Liver Cancer
4 Metastatic Liver Cancer ANDREW J. SMITH, MD, FRCSC RONALD P. DEMATTEO, MD YUMAN FONG, MD, FACS LESLIE H. BLUMGART, MD, FACS, FRCS (ENG, EDIN, GLAS) The management of hepatic metastases has become more
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationEstimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis
Jpn J Clin Oncol 2005;35(1)18 22 doi:10.1093/jjco/hyi010 Estimation of the Time of Pulmonary Metastasis in Colorectal Cancer Patients with Isolated Synchronous Liver Metastasis Sotaro Sadahiro 1, Toshiyuki
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationCurrent Controversies in the Surgical Management of Colorectal Cancer Metastases to the Liver
Current Controversies in the Surgical Management of Colorectal Cancer Metastases to the Liver Risa Small BA, Nir Lubezky MD and Menahem Ben-Haim MD Liver Surgery Unit, Department of Surgery B, Tel Aviv
More informationSelection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
Annals of Surgical Oncology, 13(10): 1261 1268 DOI: 10.1245/s10434-006-9023-y Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement Chusilp Charnsangavej, MD,
More informationManagement of Colorectal Liver Metastases
Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver
More informationHepatic arterial infusion pump chemotherapy for colorectal liver metastases: an old technology in a new era
Curr Oncol, Vol. 21, pp. e116-121; doi: http://dx.doi.org/10.3747/co.21.1592 HAI PUMP CHEMOTHERAPY FOR CRC METASTASIS REVIEW ARTICLE Hepatic arterial infusion pump chemotherapy for colorectal liver metastases:
More informationTechniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.
Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D. Department of Surgery Grand Rounds University of Kentucky January 15, 2014 Metastatic Colorectal Cancer (CRC)
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS:
Improved Survival after Resection of Liver and Lung Colorectal Metastases Compared with Liver-Only Metastases: A Study of 112 Patients with Limited Lung Metastatic Disease Antoine Brouquet, MD, Jean Nicolas
More informationEvolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010
Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010 Molecular mechanisms for cancer Prevention and screening Molecular
More informationManagement of Advanced Colorectal Cancer in Older Patients
Review Article [1] April 15, 2005 By Stuart M. Lichtman, MD, FACP [2] Many elderly individuals have substantial life expectancy, even in the setting of significant illness. There is evidence to indicate
More informationDr Adam Bartlett. General Surgeon Senior Lecturer University of Auckland Auckland City Hospital
Dr Adam Bartlett General Surgeon Senior Lecturer University of Auckland Auckland City Hospital 11:05-11:15 Hepatic Metastectomy is Associated with Improved Survival Where is everyone? Hepatic Metastectomy
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationEfficacy of Neoadjuvant Chemotherapy Regimens Prior to Resection of Colorectal Liver Metastases
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2-11-2008 Efficacy of Neoadjuvant Chemotherapy Regimens Prior to Resection
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationIntroduction. Case Report
Case Report A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer Yasuhito
More informationPrimary tumor with synchronous metastases
Metastatic colorectal cancer: special clinical situations Primary tumor with synchronous metastases Stefan Heinrich & Hauke Lang Department of General, Visceral and Transplantation Surgery University Hospital
More informationSurgical management of colorectal liver metastases
Page 1 of 5 Surgical Surgical management of colorectal liver metastases KC Choong 1, JB Ammori 1* Abstract Introduction Colorectal cancer is the fourth most common malignancy and the second most common
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationclinical practice guidelines
Annals of Oncology 21 (Supplement 5): v93 v97, 2010 doi:10.1093/annonc/mdq222 Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment E. Van Cutsem 1, B. Nordlinger 2 & A. Cervantes
More informationHepatic Arterial Infusion of Chemotherapy for Hepatic Metastases From Colorectal Cancer
Hepatic arterial infusion of chemotherapy still plays a role in selected patients with colorectal cancer and hepatic metastases. Annie Toja. Antibes, France, Leisure Boats. Acrylic. Hepatic Arterial Infusion
More informationKaoru Takeshima, Kazuo Yamafuji, Atsunori Asami, Hideo Baba, Nobuhiko Okamoto, Hidena Takahashi, Chisato Takagi, and Kiyoshi Kubochi
Case Reports in Surgery Volume 2016, Article ID 4548798, 5 pages http://dx.doi.org/10.1155/2016/4548798 Case Report Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid
More informationNICE Health Technology Re-appraisal. Submission of the British Association of Surgical Oncology- The Association for Cancer Surgery
NICE Health Technology Re-appraisal The use of irinotecan, oxaliplatin and raltitrexed in the treatment of advanced colorectal cancer (review of guidance No. 33) Submission of the British Association of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Colorectal cancer: diagnosis and management of colorectal cancer 1.1 Short title Colorectal cancer 2 The remit The Department
More informationColorectal Liver Metastases
J Gastrointest Surg (2013) 17:195 202 DOI 10.1007/s11605-012-2022-3 EVIDENCE-BASED CURRENT SURGICAL PRACTICE Colorectal Liver Metastases Ching-Wei D. Tzeng & Thomas A. Aloia Received: 22 July 2012 /Accepted:
More informationTwo-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors
ANNALS OF SURGERY Vol. 232, No. 6, 777 785 2000 Lippincott Williams & Wilkins, Inc. Two-Stage Hepatectomy: A Planned Strategy to Treat Irresectable Liver Tumors René Adam, MD, PhD, Alexis Laurent, MD,
More informationCOLORECTAL CANCER 44
COLORECTAL CANCER 44 Colorectal Cancer Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Stuart M. Lichtman, MD Memorial Sloan-Kettering Cancer Center Commack,
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationClinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131
Colorectal cancer: diagnosis and management Clinical guideline Published: 1 November 2011 nice.org.uk/guidance/cg131 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationManchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases
Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases Date: April 2015 Date for review: April 2018 1. Principles The recognised specialist HPB MDT for Greater
More informationColon, or Colorectal, Cancer Information
Colon, or Colorectal, Cancer Information Definition Colon, or colorectal, cancer is cancer that starts in the large intestine (colon) or the rectum (end of the colon). Other types of cancer can affect
More informationEvaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant Therapy of Locally Advanced Rectal Cancer
Efficacy of Modified De Gramont and FOLFOX4 Regimens for Locally Advanced Rectal Cancer RESEARCH COMMUNICATION Evaluation of the Efficacy of Modified De Gramont and Modified FOLFOX4 Regimens for Adjuvant
More informationNomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases
Original article Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases K. Imai 1,2,5, M.-A. Allard 1,2,4, C. Castro Benitez 1,2,4,E.Vibert 1,3,4, A. Sa
More informationCASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION
CASE STUDIES IN COLORECTAL CANCER: A ROUNDTABLE DISCUSSION PROVIDED AS AN EDUCATIONAL SERVICE BY THE INSTITUTE FOR CONTINUING HEALTHCARE EDUCATION SUPPORTED BY AN EDUCATIONAL GRANT FROM GENENTECH LEARNING
More information8 Giornata Onco-ematologica Varesina
Azienda Ospedaliera Sant Antonio Abate di Gallarate 8 Giornata Onco-ematologica Varesina Le esperienze di eccellenza del DIPO di Varese Metastasi epatiche da tumore del colon-retto: terapia medica in funzione
More informationTrends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma
Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma Taylor S. Riall, MD, PhD CERCIT Workshop October 19, 2012 Department of Surgery Center for Comparative Effectiveness
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationRandomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients With KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases
Published Ahead of Print on April 8, 2013 as 10.1200/JCO.2012.44.8308 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2012.44.8308 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More informationORIGINAL ARTICLE. Effectiveness of Positron Emission Tomography for Predicting Chemotherapy Response in Colorectal Cancer Liver Metastases
ORIGINAL ARTICLE Effectiveness of Positron Emission Tomography for Predicting Chemotherapy Response in Colorectal Cancer Liver Metastases Evan S. Glazer, MD; Karen Beaty, PA-C; Eddie K. Abdalla, MD; J.
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationPerioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection
Original Study Perioperative With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection Anastasia Constantinidou, 1 David Cunningham, 1 Fatima Shurmahi, 1 Uzma
More informationPharmacy Management Drug Policy
11/13, 10/12, 11/11, 1, 6/10, Page 1 of 5 DESCRIPTION: Cetuximab is a recombinant humanized monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor
More informationThe efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different line setting*
Chinese-German J Clin Oncol DOI 10.1007/s10330-014-1295-2 April 2014, Vol. 13, No. 4, P169 P173 The efficacy of bevacizumab in Chinese patients with metastatic colorectal cancer and its effect in different
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
More informationAintree University Hospital
Aintree University Hospital Liverpool, UK Evolving role of DEBIRI with DC Bead - TACE in mcrc Hassan Z Malik MD FRCS Consultant Hepatobiliary Surgeon Hassan Z Malik is a consultant to Biocompatibles UK
More informationUnresectable or boarderline resectable disease
ESMO Preceptorship Colorectal Cancer Nov 2016 Barcelona Unresectable or boarderline resectable disease Claus-Henning Köhne Klinik für Onkologie und Hämatologie North West German Cancer Center (NWTZ) Learning
More informationA clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
Med Oncol (2014) 31:839 DOI 10.1007/s12032-014-0839-1 ORIGINAL PAPER A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach Michaela Jung Annica Holmqvist Xiao-Feng Sun
More informationRadiation Therapy for Resectable Colon Cancer
Review Article [1] February 01, 2006 By Brian G. Czito, MD [2], Johanna C. Bendell, MD [3], and Christopher G. Willett, MD [4] Colon cancer is a major public health problem. The primary treatment is resection.
More informationThe Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative Chemotherapy: Is the Treatment Worthwhile?
1179 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(7): 1179-1186. doi: 10.7150/jca.18091 The Role of Adjuvant Chemotherapy for Colorectal Liver Metastasectomy after Pre-Operative
More informationImpact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
Okada et al. World Journal of Surgical Oncology (2017) 15:162 DOI 10.1186/s12957-017-1226-0 RESEARCH Open Access Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy Shunji Okada,
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationTherapy for Metastatic Colorectal Cancer
Therapy for Metastatic Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA Learning Objectives Key
More informationHow to integrate surgery in the treatment of patients with liver-only metastatic disease
How to integrate surgery in the treatment of patients with liver-only metastatic disease Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB)
More informationThe International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice
Editorial The International Duration Evaluation of Adjuvant Chemotherapy study: implications for clinical practice Marwan Fakih Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive
More informationSystemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice
Original Contribution Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice By Gregory P. Hess, MD, MSc, Peter Feng Wang,
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationImpact of Adjuvant Chemotherapy in Patients With Curatively Resected Stage IV Colorectal Cancer
Impact of in Patients With Curatively Resected Stage IV Colorectal Cancer Hirotoshi Kobayashi, MD, FACS, Kenjiro Kotake, MD, and Kenichi Sugihara, MD, Study Group for Peritoneal Metastasis from Colorectal
More informationNEVENA DAMJANOV, JARED WEISS, DANIEL G. HALLER
The Oncologist Gastrointestinal Cancer Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease NEVENA DAMJANOV, JARED WEISS, DANIEL G. HALLER University
More informationLiver surgery for colorectal liver metastases. Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham
Liver surgery for colorectal liver metastases Keith Roberts, Consultant Liver Transplant and Liver/Pancreas Surgeon University Hospitals Birmingham Introduction: what do we do? UHB Liver Unit: Liver resections
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationGhosts in the Machine: Jonathan B. Koea MD; FRACS. Department of Surgery Auckland Hospital Auckland New Zealand
Ghosts in the Machine: Patient Journeys Through Cancer Treatment Jonathan B. Koea MD; FRACS. Department of Surgery Auckland Hospital Auckland New Zealand Age-Standardised Cancer Incidence (100,000 population)
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationImage Guidance Improves Localization of Sonographically Occult Colorectal Liver Metastases
Image Guidance Improves Localization of Sonographically Occult Colorectal Liver Metastases Universe Leung a, Amber L. Simpson a,b, Lauryn B. Adams a, William R. Jarnagin a, Michael I. Miga b, and T. Peter
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More information